CN111936165A - 治疗溃疡性结肠炎的方法 - Google Patents

治疗溃疡性结肠炎的方法 Download PDF

Info

Publication number
CN111936165A
CN111936165A CN201980023563.3A CN201980023563A CN111936165A CN 111936165 A CN111936165 A CN 111936165A CN 201980023563 A CN201980023563 A CN 201980023563A CN 111936165 A CN111936165 A CN 111936165A
Authority
CN
China
Prior art keywords
administered
dose
antibody
mirikizumab
maintenance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980023563.3A
Other languages
English (en)
Chinese (zh)
Inventor
J·B·卡纳万
S·W·弗里德里希
K·A·克鲁格
C·米尔希
J·L·塔特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN111936165A publication Critical patent/CN111936165A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201980023563.3A 2018-03-30 2019-03-28 治疗溃疡性结肠炎的方法 Pending CN111936165A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650314P 2018-03-30 2018-03-30
US62/650,314 2018-03-30
PCT/US2019/024633 WO2019191464A1 (en) 2018-03-30 2019-03-28 Methods of treating ulcerative colitis

Publications (1)

Publication Number Publication Date
CN111936165A true CN111936165A (zh) 2020-11-13

Family

ID=66429483

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980023563.3A Pending CN111936165A (zh) 2018-03-30 2019-03-28 治疗溃疡性结肠炎的方法

Country Status (29)

Country Link
US (2) US12152072B2 (https=)
EP (2) EP4327866B1 (https=)
JP (4) JP7119114B2 (https=)
KR (1) KR102552693B1 (https=)
CN (1) CN111936165A (https=)
AU (2) AU2019243283C1 (https=)
BR (1) BR112020018099A2 (https=)
CA (1) CA3095297A1 (https=)
DK (2) DK3773715T3 (https=)
EA (1) EA202091989A1 (https=)
ES (2) ES3063700T3 (https=)
FI (2) FI4327866T3 (https=)
HR (2) HRP20260275T1 (https=)
HU (1) HUE067445T2 (https=)
IL (2) IL277514B2 (https=)
LT (2) LT3773715T (https=)
MA (2) MA52216B1 (https=)
MD (2) MD4327866T2 (https=)
MX (1) MX2020010269A (https=)
MY (1) MY202368A (https=)
PL (2) PL4327866T3 (https=)
PT (2) PT4327866T (https=)
RS (2) RS67806B1 (https=)
SG (1) SG11202009526RA (https=)
SI (2) SI3773715T1 (https=)
TW (2) TWI744617B (https=)
UA (1) UA128578C2 (https=)
WO (1) WO2019191464A1 (https=)
ZA (1) ZA202005388B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024255867A1 (zh) * 2023-06-16 2024-12-19 信达生物制药(苏州)有限公司 重组抗白介素23p19亚基抗体在治疗炎症性肠病中的用途

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7805788B2 (ja) 2019-05-23 2026-01-26 ヤンセン バイオテツク,インコーポレーテツド Il-23及びtnfアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
BR112022015996A2 (pt) * 2020-02-14 2022-10-11 Janssen Biotech Inc Método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23
IL298389A (en) 2020-05-21 2023-01-01 Janssen Biotech Inc Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
JP7423815B2 (ja) * 2020-10-20 2024-01-29 セトラスホールディングス株式会社 治験管理装置、治験管理方法、治験管理プログラム及び治験管理システム
TW202241506A (zh) * 2021-01-06 2022-11-01 美商艾伯維有限公司 治療克羅恩氏病及潰瘍性結腸炎之方法
BR112023024064A2 (pt) * 2021-05-20 2024-01-30 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
JP2024521748A (ja) * 2021-05-28 2024-06-04 イーライ リリー アンド カンパニー 潰瘍性大腸炎に関与する遺伝子の抗il-23p19抗体調節
US20230159633A1 (en) * 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
AU2023383916A1 (en) * 2022-11-22 2025-07-10 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
TW202500184A (zh) 2023-03-10 2025-01-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法
WO2025170982A2 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
WO2026060205A1 (en) 2024-09-13 2026-03-19 Eli Lilly And Company PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2452694T1 (sl) * 2005-06-30 2019-05-31 Janssen Biotech, Inc. Protitelesa proti-IL-23, sestavki in postopki uporabe
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
ES2708988T3 (es) 2007-02-23 2019-04-12 Merck Sharp & Dohme Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
JP2012507723A (ja) * 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
MX2019000046A (es) * 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
AR094877A1 (es) 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
MX2020009265A (es) * 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024255867A1 (zh) * 2023-06-16 2024-12-19 信达生物制药(苏州)有限公司 重组抗白介素23p19亚基抗体在治疗炎症性肠病中的用途

Also Published As

Publication number Publication date
SI4327866T1 (sl) 2026-04-30
MA52216A (fr) 2021-02-17
MX2020010269A (es) 2020-11-06
RS67806B1 (sr) 2026-03-31
PT3773715T (pt) 2024-05-27
LT4327866T (lt) 2026-03-10
WO2019191464A1 (en) 2019-10-03
US12152072B2 (en) 2024-11-26
AU2023248103B2 (en) 2026-02-05
HRP20240904T1 (hr) 2024-10-11
ES2983809T3 (es) 2024-10-24
TWI744617B (zh) 2021-11-01
CA3095297A1 (en) 2019-10-03
HRP20260275T1 (hr) 2026-04-10
DK4327866T3 (da) 2026-02-23
ES3063700T3 (en) 2026-04-20
NZ767902A (en) 2024-05-31
IL277514B2 (en) 2024-11-01
MY202368A (en) 2024-04-24
JP2025020134A (ja) 2025-02-12
SI3773715T1 (sl) 2024-06-28
JP2022169562A (ja) 2022-11-09
ZA202005388B (en) 2025-05-28
MD3773715T2 (ro) 2024-10-31
EA202091989A1 (ru) 2021-01-13
US20250034243A1 (en) 2025-01-30
LT3773715T (lt) 2024-06-25
FI3773715T3 (fi) 2024-05-30
SG11202009526RA (en) 2020-10-29
MA52216B1 (fr) 2024-07-31
MD4327866T2 (ro) 2026-04-30
PL3773715T3 (pl) 2024-08-19
JP7331219B2 (ja) 2023-08-22
US20210032325A1 (en) 2021-02-04
AU2023248103A1 (en) 2023-11-09
BR112020018099A2 (pt) 2020-12-22
IL312807B1 (en) 2025-02-01
PL4327866T3 (pl) 2026-04-20
TW201946657A (zh) 2019-12-16
TW202206104A (zh) 2022-02-16
EP4327866A2 (en) 2024-02-28
EP4327866B1 (en) 2025-12-10
JP2023166388A (ja) 2023-11-21
JP2021517156A (ja) 2021-07-15
IL312807A (en) 2024-07-01
DK3773715T3 (da) 2024-05-27
MA67901B1 (fr) 2026-02-27
RS65661B1 (sr) 2024-07-31
IL277514B1 (en) 2024-07-01
UA128578C2 (uk) 2024-08-21
KR102552693B1 (ko) 2023-07-07
EP3773715A1 (en) 2021-02-17
AU2019243283B2 (en) 2023-07-27
PT4327866T (pt) 2026-02-17
HUE067445T2 (hu) 2024-10-28
AU2019243283A1 (en) 2020-09-24
JP7571225B2 (ja) 2024-10-22
IL312807B2 (en) 2025-06-01
FI4327866T3 (fi) 2026-02-18
JP7119114B2 (ja) 2022-08-16
IL277514A (en) 2020-11-30
TWI837532B (zh) 2024-04-01
EP3773715B1 (en) 2024-05-08
EP4327866A3 (en) 2024-03-20
KR20200128101A (ko) 2020-11-11
AU2019243283C1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
JP7331219B2 (ja) 潰瘍性大腸炎を治療する方法
JP7703513B2 (ja) 抗ガレクチン9抗体と化学療法剤の組合せがん治療
US20240043543A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
TW202103734A (zh) 治療克隆氏症(crohn's disease)的方法
BR112021010516A2 (pt) Tratamento tópico de diarreia, colite ou enterocolite induzida por inibidor de ponto de verificação imunológico usando anticorpos e fragmentos dos mesmos
HK40101440A (en) Mirikizumab in the treatment of ulcerative colitis
HK40036550A (en) Mirikizumab in the treatment of ulcerative colitis
HK40036550B (en) Mirikizumab in the treatment of ulcerative colitis
EA049081B1 (ru) Способы лечения язвенного колита

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination